Understanding Key Drivers and Growth Opportunities in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market: Trends and Market Size Insights
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Major Innovations Are Driving the Accelerated Growth of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The growing prevalence of chronic diseases is anticipated to drive the expansion of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market. Chronic diseases are long-term conditions that develop gradually and persist for extended periods, often requiring ongoing medical attention. The increase in chronic diseases is linked to factors such as aging populations, sedentary lifestyles, poor diets, rising obesity rates, and exposure to environmental pollutants. ATTR-CM treatment aids by stabilizing transthyretin, reducing amyloid accumulation, enhancing heart function, and alleviating symptoms to better manage associated chronic conditions. For example, in September 2023, the World Health Organization reported that chronic diseases accounted for 74% of all deaths globally, with 41 million deaths annually. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the increasing prevalence of chronic diseases is driving the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
#What is the Growth Potential of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, and How Will It Perform by 2034?
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market has expanded exponentially, growing from $10.36 billion in 2024 to $13.32 billion in 2025 at a CAGR of 28.5%. Factors contributing to this growth include the rising prevalence of ATTR-CM, an increasing geriatric patient population, heightened awareness among healthcare professionals and patients, and improvements in healthcare services.
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is expected to experience exponential growth, reaching $35.93 billion by 2029, with a CAGR of 28.2%. The rapid growth will be driven by an increasing prevalence of transthyretin amyloidosis, improved diagnosis of neuropathic disorders, a growing aging population, rising demand for targeted drugs to manage symptoms of this rare condition, and increasing demand for healthcare services. Major trends anticipated include advancements in diagnostic technologies, the development of innovative therapy management techniques, the introduction of targeted treatments for transthyretin amyloidosis, improvements in diagnostic methods, and the adoption of cardiac MRI techniques.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304
What Are the Most Significant Market Trends Transforming theTransthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
In the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, companies are developing oral medications to target and stabilize transthyretin proteins or reduce amyloid fibril buildup in the heart. For example, in November 2024, BridgeBio Pharma received FDA approval for Attruby (acoramidis), an oral medication that stabilizes the transthyretin protein and reduces heart-related complications from ATTR-CM, showing rapid benefits for patients.
What Are the Top Market Players Propelling the Growth of theTransthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG
Order Your Report Now For A Swift Delivery:
Which Primary Segments of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Are Driving Growth and Industry Transformations?
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp
Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?# Market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market 2025, By The Business Research Company:
Hepatitis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2025
Hepatitis Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
